Stocktoria
WEST PHARMACEUTICAL SERVICES INC WST
WEST PHARMACEUTICAL SERVICES INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1B | $2.9B | $2.9B | $2.9B | $2.8B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B |
| Gross profit | $1.1B | $998.5M | $1.1B | $1.1B | $1.2B | $767.8M | $605.7M | $545.4M | $512.9M | $501.4M |
| R&D expense | $74.3M | $69.1M | $68.4M | $58.5M | $52.8M | $46.9M | $38.9M | $40.3M | $39.1M | $36.8M |
| SG&A expense | $393.6M | $338.5M | $353.4M | $316.9M | $362.8M | $302.0M | $272.7M | $262.9M | $246.0M | $239.6M |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M | $406.9M | $296.6M | $240.3M | $225.8M | $195.2M |
| Interest expense | — | — | $9.0M | $7.9M | $8.2M | $8.2M | $8.5M | $8.4M | $7.8M | $8.1M |
| Income tax | $121.6M | $107.5M | $122.3M | $114.7M | $107.2M | $72.5M | $59.0M | $41.4M | $80.9M | $54.4M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | $346.2M | $241.7M | $206.9M | — | — |
| EPS (diluted) | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M | $472.5M | $367.2M | $288.6M | $263.3M | $219.4M |
| Free cash flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M | $298.1M | $240.8M | $183.9M | $132.5M | $49.2M |
| Cash & equivalents | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M | $615.5M | $439.1M | $337.4M | $235.9M | $203.0M |
| Inventory | $443.9M | $377.0M | $434.7M | $414.8M | $378.4M | $321.3M | $235.7M | $214.5M | $215.2M | $199.3M |
| Total assets | $4.3B | $3.6B | $3.8B | $3.6B | $3.3B | $2.8B | $2.3B | $2.0B | $1.9B | $1.7B |
| Total liabilities | $1.1B | $961.1M | $948.5M | $931.9M | $978.4M | $939.3M | $768.2M | $582.6M | $582.9M | $599.2M |
| Shareholders' equity | $3.2B | $2.7B | $2.9B | $2.7B | $2.3B | $1.9B | $1.6B | $1.4B | $1.3B | $1.1B |
Growth · year-over-year · Revenue CAGR 8.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +6.3% | -1.9% | +2.2% | +2.0% | +31.9% | +16.7% | +7.1% | +7.4% | +6.0% | +7.8% |
| Net income growth | +0.2% | -17.0% | +1.3% | -11.5% | +91.2% | +43.2% | +16.8% | — | — | — |
| EPS growth | +1.5% | -15.1% | +1.9% | -10.8% | +89.7% | +42.4% | +17.2% | +37.7% | +4.2% | +46.9% |
| Free cash flow growth | +69.6% | -33.3% | -5.7% | +32.9% | +10.9% | +23.8% | +30.9% | +38.8% | +169.3% | -39.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.